Hu Huilin, Shen Liang
Department of Cardiology, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China.
Exp Ther Med. 2021 May;21(5):464. doi: 10.3892/etm.2021.9895. Epub 2021 Mar 5.
Drug-eluting stents are the standard revascularization strategy for the treatment of symptomatic coronary artery disease. However, in-stent restenosis (ISR), stent thrombosis and reinfarction of target lesions following stent implantation present challenges. Drug-coated balloons (DCBs), which deliver antiproliferative drugs into the vessel wall without stent implantation, are a novel treatment option for percutaneous coronary intervention and have been proven to act as a promising strategy in the treatment of ISR and coronary small vessel disease. However, their role in acute myocardial infarction (AMI) remains unclear. The present review discusses current evidence for the treatment of AMI with DCBs.
药物洗脱支架是治疗有症状冠状动脉疾病的标准血运重建策略。然而，支架植入后支架内再狭窄（ISR）、支架血栓形成和靶病变再梗死带来了挑战。药物涂层球囊（DCB）在不植入支架的情况下将抗增殖药物输送到血管壁，是经皮冠状动脉介入治疗的一种新选择，并且已被证明是治疗ISR和冠状动脉小血管疾病的一种有前景的策略。然而，它们在急性心肌梗死（AMI）中的作用仍不明确。本综述讨论了使用DCB治疗AMI的当前证据。
